Amgen Inc. Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount
Amgen Inc. (AMGN) reported Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount of $152.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-14.
Discontinued › Notes › Investments › Debt and Equity Securities › Equity Securities without Readily Determinable Fair Value, Annual Amount
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount · last filed 2024-02-14
- Amgen Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2021-09-30 was $94.00M, a 683.33% increase year-over-year.
- Amgen Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2020-09-30 was $12.00M.
- Amgen Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2021 was $152.00M.
| Period end | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 12 month |
|---|---|---|---|
| 2021-12-31 | $152.00M 10-K · filed 2024-02-14 | ||
| 2021-09-30 | $94.00M 10-Q · filed 2021-11-03 | $129.00M 10-Q · filed 2021-11-03 | |
| 2020-09-30 | $12.00M 10-Q · filed 2021-11-03 | $20.00M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |